Companies Cryptocurrencies
Prevail Therapeutics Inc
Prevail Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 20/06/2019
CEO: Dr. Asa Abeliovich
Biotechnology Healthcare đź”—
  • PRVL
  • price
  • market cap
  • changes
If you bought

shares of Prevail Therapeutics Inc (PRVL) on
You would have made
Old Price $12 Current Price $12

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 48 full-time employees. The firm is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. The company is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The firm is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Address: 430 E 29th St Ste 940 New York City NEW YORK 10016

Stay updated.